Abstract
BackgroundHereditary angioedema (HAE) is a rare but life-threatening condition. HAE types I and II (HAE-1/2) result from C1-inhibitor (C1–INH) deficiency. However, recent genetic analysis has established a new type of HAE with normal C1–INH (HAEnC1-INH). The mutations of factor XII, plasminogen, angiopoietin 1, and kininogen 1 genes may be the cause of HAEnC1-INH. Nevertheless, other causative molecules (HAE-unknown) may be involved. The Japanese therapeutic environment for HAE has been improving owing to the self-subcutaneous injection of icatibant, which was approved for the treatment of acute attack and enables early therapy. Erythema marginatum (EM) is a visible prodromal symptom which occasionally occurs prior to an angioedema attack; hence, recognizing the risk of an acute attack is important for early treatment. However, the detailed characteristics of EM remain unclear. In this study, we first investigated the clinical manifestations of EM in Japanese patients with HAE. MethodsA 20-point survey was developed and distributed to 40 physicians to gather clinical data on EM from patients with HAE. ResultsData on 68 patients with HAE (58 patients with HAE-1/2 and 10 patients with HAE-unknown) were collected. Of the patients with HAE-1/2, 53.4% experienced EM, whereas 43.1% did not. The forearm was the most frequent area of EM (64.5%), followed by the abdomen (29.0%) and upper arm and precordium (19.3%). Of the HAE-1/2 patients with EM, 41.9% always had angioedema following EM, while 29.0% always had colocalization of EM with angioedema. Moreover, 3.2% showed a correlation between the awareness of EM and severity of an angioedema attack. In 60.9% of HAE-1/2 patients with EM, the interval between the awareness of EM and appearance of angioedema was <3 h. Of the patients with HAE-unknown, 30.0% also experienced EM. ConclusionWe confirmed that more than one-half of Japanese patients with HAE-1/2 and one-third of those with HAE-unknown develop EM as the prodromal symptom of an angioedema attack. Physicians should communicate the significance of EM to patients with HAE to prepare them for possible imminent attacks.
Highlights
3.2% showed a correlation between the awareness of Erythema marginatum (EM) and severity of an angioedema attack
Physicians should communicate the significance of EM to patients with Hereditary angioedema (HAE) to prepare them for possible imminent attacks
Hereditary angioedema (HAE) types I and II (HAE-1/2) refer to an autosomal dominant and potentially life-threatening disease caused by mutations of the gene “serpin family G member 1” (SERPING1) encoding the C1-inhibitor (C1–INH)
Summary
Hereditary angioedema (HAE) types I and II (HAE-1/2) refer to an autosomal dominant and potentially life-threatening disease caused by mutations of the gene “serpin family G member 1” (SERPING1) encoding the C1-inhibitor (C1–INH). The injection of pdC1-INH is performed by medical professionals at medical facilities and self-injection has not been approved.[3] At the end of 2018, the self-subcutaneous injection of icatibant (bradykinin-B2-receptor antagonist [BKB2-A]), which enables early therapy, was approved for the treatment of acute attacks. This development has offered benefits to patients with HAE in terms of quality of life. We first investigated the clinical manifestations of EM in Japanese patients with HAE
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.